Skateboarder Shawn Connolly was one of the participants in the feasibility trial. Image credit: University of California, San Francisco.
A new type of self-adjusting neuromodulation is poised to transform the landscape of neurology, as per analyst reaction to results from two studies evaluating the technology.
The pair of studies, conducted at University of California, San Francisco (UCSF), tested what it calls ‘intelligent brain pacemakers’ – an implant that uses an approach called adaptive brain stimulation (aDBS). This method involves using artificial intelligence (AI) to spot changes in patient symptoms via brain activity monitoring and then delivering personalised care.
“As the landscape of medical treatment evolves, particularly with these sophisticated systems, a promising shift is being witnessed towards more personalised and effective treatment strategies for neurological conditions,” Says GlobalData medical device analyst Cynthia Stinchcombe.
Results from the studies, published in Nature Communications and Nature Medicine in February and August respectively, demonstrated the promise of the platform in patients with Parkinson’s disease, helping patients carry out activities such as sleeping at night and movement problems during day.
The closed-loop technology intervenes with precisely calibrated pulses of electricity when it spots deviations of brain activity and works alongside Parkinson’s medication. This is different to regular DBS, which delivers constant pulses.
“The increasing integration of advanced technology in the management of neurological disorders fits into the broader industry shift towards precision medicine, as reflected in the FDA’s recent push for innovative solutions in Parkinson’s disease management,” explains Stinchcombe.
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
View profiles in store
Company Profile – free
sample
Your download email will arrive shortly
We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form
By GlobalData
Country *
UK
USA
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bonaire, Sint
Eustatius
and
Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean
Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos Islands
Colombia
Comoros
Congo
Democratic Republic
of
the Congo
Cook Islands
Costa Rica
Côte d”Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern
Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and
McDonald
Islands
Holy See
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
North Korea
South Korea
Kuwait
Kyrgyzstan
Lao
Latvia
Lebanon
Lesotho
Liberia
Libyan Arab Jamahiriya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia,
The
Former
Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint
Helena,
Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Pierre and Miquelon
Saint Vincent and
The
Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South
Georgia
and The South
Sandwich Islands
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan
Tajikistan
Tanzania
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
US Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela
Vietnam
British Virgin Islands
US Virgin Islands
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
Kosovo
Industry *
Academia & Education
Aerospace, Defense &
Security
Agriculture
Asset Management
Automotive
Banking & Payments
Chemicals
Construction
Consumer
Foodservice
Government, trade bodies
and NGOs
Health & Fitness
Hospitals & Healthcare
HR, Staffing &
Recruitment
Insurance
Investment Banking
Legal Services
Management Consulting
Marketing & Advertising
Media & Publishing
Medical Devices
Mining
Oil & Gas
Packaging
Pharmaceuticals
Power & Utilities
Private Equity
Real Estate
Retail
Sport
Technology
Telecom
Transportation &
Logistics
Travel, Tourism &
Hospitality
Venture Capital
Tick here to opt out of curated industry news, reports, and event updates from Clinical Trials Arena.
Submit and
download
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
The studies “mark a major advancement in the management of Parkinson’s disease” according to GlobalData analysis, which also reflects the growing influence of digital technologies in neurological disease treatment.
The global market for neurological devices was valued at $12.5bn in 2023 and is forecast to reach $20.9 billion by 2033, as per a GlobalData report.
DBS has been a US Food and Drug Administration (FDA)-approved option for Parkinson’s disease patients since 1997. Whilst effective, this type of intervention does not adapt to natural fluctuations in brain activity and cannot account for changes in levels of medications patients take for the disease.
“The big shift we’ve made with adaptive DBS is that we’re able to detect, in real time, where a patient is on the symptom spectrum and match it with the exact amount of stimulation they need,” said Little, associate professor of neurology and a senior author of both studies.
Little’s colleague and senior author of the studies, Dr Philip Starr, calls it the “future of deep brain stimulation for Parkinson’s disease.”
Parkinson’s disease diagnoses are increasing amid ageing populations around the world. A 2022 study by the Parkinson’s Foundation revealed that nearly 90,000 people are diagnosed with Parkinson’s disease in the US each year. According to the Parkinson’s Foundation Parkinson’s Prevalence Project, 1.2 million people in the US will be living with Parkinson’s by 2030.
Stinchcombe says that in the face of ageing populations, the advancements being witnessed are “encouraging for those affected”.
“Emerging technologies are pivotal in broadening the horizons of neurology diagnostics and improving patient outcomes. Together with the FDA’s initiative to enhance AI-driven diagnostics, these advancements are poised to dramatically improve the landscape of neurology,” she adds.
Sign up for our daily news round-up!
Give your business an edge with our leading industry insights.
Copyright for syndicated content belongs to the linked Source link
